ENCAR-T cell therapy in Germany is a one-off treatment for certain blood cancers at qualified centres. Families usually arrive after several failed chemotherapy lines, having read that a patient’s cells can become a medicine. T cells are collected and given a laboratory-made receptor recognising a protein on cancer cells. They are then multiplied and reinfused.
Below: approved uses in Germany, the weeks to infusion, monitoring afterwards and what patients from abroad must settle before travelling; see also cancer treatment in Germany. No prices, dates or odds here: the centre decides eligibility from the records, not a website.
What CAR-T cell therapy is
It is made in steps from the patient’s own cells: apheresis separates T cells from the blood, returning the rest. At the manufacturer a viral vector inserts the chimeric antigen receptor (CAR) gene, and the cells multiply. The frozen product returns, usually for one infusion of under an hour. Manufacturing takes weeks, so bridging treatment is often needed; each batch suits only its named patient.
Approved products target CD19, a protein on B cells, or BCMA in myeloma. Healthy B cells carry the same protein and are destroyed too, so antibody levels are checked afterwards and immunoglobulin is sometimes replaced.
It is a one-off living drug given in hospital, not a course, and no substitute for a stem cell transplant but a separate route with its own indications; a tumour board decides between them. Other immune treatments: cancer immunotherapy in Germany.
Which diseases it is used for
In Europe, CAR-T is approved only for certain blood cancers: aggressive B-cell lymphomas, including diffuse large B-cell lymphoma, after previous treatment, plus follicular and mantle cell lymphoma; B-cell acute lymphoblastic leukaemia in children and young adults up to 25 and, with other products, in adults from 26; and multiple myeloma, via BCMA, after at least one or two prior lines depending on the product. Approvals change and rules are narrow: pathology must confirm diagnosis and surface markers; prior treatment must match the label. The German Cancer Research Center’s Krebsinformationsdienst explains the method.
Solid tumours such as lung, bowel or breast cancer are excluded: there CAR-T is still research, in Germany only within clinical trials. If offered as routine paid treatment for a solid tumour, ask for the trial number and protocol.
How the weeks from referral to infusion run
Assessment comes first: the centre reviews pathology, immunophenotype (surface markers), imaging, treatment history and heart, lung, liver and kidney function, and rules out active infection; a lumbar puncture or fresh biopsy is sometimes needed. The answer is an apheresis slot or a finding of unsuitability, which is also information, not a refusal to help.
Cell collection through a large vein takes a few hours; during manufacture, bridging treatment holds the disease. A few days before infusion, short chemotherapy makes room for the new cells: this lymphodepletion is part of the procedure, not an extra course.
The first two weeks after infusion are spent in hospital, watched for cytokine release syndrome (immune-driven fever, falling blood pressure, breathlessness) and neurological effects like confusion or word-finding difficulty. Both are treatable; centres keep the drugs and an intensive care bed ready, precisely why only a few hospitals give it. Patients then stay nearby for at least two or four weeks after infusion, depending on the label; follow-up and antibody checks continue for months.
Where it is done in Germany
CAR-T cell therapy in Germany is given only at centres qualified for the individual product, with apheresis, a cell therapy laboratory, intensive care and stem cell transplant experience. Patients choose not a city but a centre accepting the case.
For example, Professor Florian Bassermann directs the clinic for internal medicine III at Munich’s Klinikum rechts der Isar, whose systemic treatment includes CAR-T and autologous and allogeneic stem cell transplants, which belongs to the Comprehensive Cancer Center München and the German Cancer Consortium; Professor Sebastian Scholl leads haematology and oncology at Helios Klinikum Erfurt, lists CAR-T therapy and stem cell transplantation among his areas and heads its certified haematology centre; Professor Justus Duyster directs the clinic for internal medicine I (haematology, oncology, stem cell transplantation) at the University Hospital Freiburg, which includes the tumour immunology and immune regulation department of Professor Robert Zeiser, 2025 winner of the Gottfried Wilhelm Leibniz Prize. Since 2024 the hospital has also had a Centre for Cell and Gene Therapy (CGF).
What a patient from abroad has to settle first
First the records: pathology report with immunophenotyping, full treatment history with dates and doses, recent imaging on disc, current blood counts and organ function, any previous transplant reports, all translated. Incomplete records most often stall an assessment, and time matters more here than in most treatments.
Then logistics: not an outpatient trip but weeks in and near hospital, a companion, accommodation, a visa for the whole stay and a written cost estimate before booking, as treatment is self-paid without German cover. No one can promise a result; a second opinion on whether CAR-T is right at all is legitimate, ideally before apheresis.
Frequently asked questions
Who qualifies for CAR-T?
Patients with B-cell lymphoma, B-cell acute lymphoblastic leukaemia or multiple myeloma may qualify when the disease has returned or resisted earlier treatment and the case matches the label. The centre also checks fitness, organ function and infection, and decides from the records.
How long does CAR-T take?
It takes weeks, follow-up months. After record review and cell collection, manufacturing takes several weeks. After infusion, patients usually spend about two weeks in hospital, then stay nearby as the label requires. Check-ups continue for months; monitoring for late complications is life-long.
How risky is CAR-T?
Risks are serious, so only centres with intensive care give it. The main complications, cytokine release syndrome and neurological effects, are treatable. Low blood counts and antibodies can persist, raising infection risk. In 2024 the EMA safety committee found that rare secondary T-cell cancers can occur; monitoring is life-long.
How AlenMed organises treatment
After first contact, a medical interpreter translates the records for haematology departments running cellular therapy, which reply whether an approved product or a trial fits, what they need next and possible dates; medical visa paperwork is prepared alongside.
AlenMed has 86 partner hospitals in 38 cities and 345 doctors, with its office in Munich. A coordinator books appointments, interprets at consultations and on the ward, helps with accommodation near the centre and ensures the discharge letter and follow-up plan reach the doctor at home.
This material is for information only and not an offer; a doctor decides treatment at a face-to-face examination.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
